Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy
- 作者: Artamonova E1
-
隶属关系:
- РОНЦ им. Н.Н.Блохина РАМН, Москва
- 期: 卷 11, 编号 4 (2009)
- 页面: 29-35
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26798
- ID: 26798
如何引用文章
全文:
详细
Рак молочной железы (РМЖ) остается одной из наиболее серьезных проблем здравоохранения как в России, так и во всем мире. Ежегодно выявляется более 1 млн 200 тыс. новых случаев РМЖ, что составляет 10% от общего числа онкологических заболеваний.Несмотря на продолжающийся рост заболеваемости РМЖ, показатели смертности от него в ряде стран прогрессивно снижаются: за период с 1990 по 2002 г. в Западной Европе и США зарегистрировано сокращение смертности на 17 и 24% соответственно. Этот факт обусловлен не только совершенствованием методов ранней диагностики и широким внедрением скрининговых программ, но и проведением современной адекватной адъювантной химиотерапии (ХТ) и гормонотерапии. Применение адъювантного системного лечения после радикального оперативного вмешательства достоверно снижает риск рецидива и смерти от прогрессирования
参考
- Семиглазов В.Ф., Семиглазов В.В., Нургазиев К.Ш. Обоснование стандартов лечения рака молочной железы. М., 2007; с. 202–3.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; V365: 1687–717.
- EBCTCG New advances in the treatment of breast cancer. San Antonio, 2007.
- Goldhirsch A, Ingle J.N., Gelber R.D. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319–29.
- Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node - negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
- Zilembo N, Bajetta E, Martinetti A et al. Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA). Eur J Cancer 2001; 37(Suppl. 6): S193.
- Gossa P.E., Qia S, Josseb R.G. et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34 (3): 384–92.
- Lohrisch C, Paridaens R, Dirix L et al. No adverse impact on serum lipids of the irreversible aromatase inactivator AromasinR (Exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization for the Research and Treatment of Cancer (Breast Group) Trial with Pharmacias' Upjohn. Proc Am Soc Clin Oncol 2001; 20 (43a): Abstr. 167.
- Kaufmann M, Bajetta E, Dirix L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double - blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399–411.
- Paridaens R.J., Dirix L.Y., Beex L.V. et al. Phase III Study Comparing Exemestane With Tamoxifen As First - Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26 (30): 4883–90.
- Coombes R.S., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen therapy after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559–70.
- Coombes R.S., Hall E, Gibson L.J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
- Bliss J.M., Kilburn L.S., Coleman R.E. et al. Disease related outcome with long term follow - up: an updated analysis of the Intergroup Exemestane Study (IES). Cancer Res 2009; 69 (Suppl.): 487s, abstr. 12.
- Mamounas E, Jeong J-H, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent - to - treat analysis of NSABP B-33. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S22 (Abstr 49).
- Saphner T, Tormey D.C., Grayet R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738–46.
- Ellis M.J., Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor - positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.
- Dowsett M, Allred C, Knox J et al. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008; 26 (7): 1059–65.
- Goldhirsch A., Wood W.S., Gelber R.D. et al. Progress and promise: high - lights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44.
- Van de Velde C, Seynaeve C, Hasenburg A et al. Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. EJC 2009; 7, 3 (Suppl.): p 1, abstr. 2BA.
- Jones S.E., Seynaeve C, Hasenburg A et al. Results of the first analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. SABS 2008.
- Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in randomized, cross - over study. J Clin Oncol 2002; 20: 751–7.
- Geisler J, King N B, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor in postmenopausal breast cancer patients. Clin Camcer Res 1998; 4: 2089–93.